847586-08-7

Upstream product

• 36476-78-5 3-azetidinecarboxylic acid 
• 3470-50-6 6-Hydroxy-1-tetralone 
• 13633-25-5 1-Bromo-4-phenylbutane 
• 1314760-20-7 C₂₂H₂₄O₂ 
• 872710-28-6 4-methyl-7-(4-phenylbutoxy)-1,2-dihydronaphthalene 
• 1314760-19-4 C₂₁H₂₆O₂ 
• 847585-55-1 6-(4-phenylbutoxy)-3,4-dihydronaphthalen-1(2H)-one 

Downstream Products

• 847584-69-4 1-{[1-methyl-6-(4-phenylbutoxy)-3,4-dihydro-2-naphthalenyl]methyl}-3-azetidinecarboxylic acid hydrochloride 

Relevant academic research and scientific papers

Method for preparing compound capable of combining S1P acceptor and its intermediate

The invention provides a method for preparing a compound capable of combining a S1P acceptor and its intermediate. The compound capable of combining the S1P acceptor can be taken as an immunosuppressant used for repulsion of the transplant organs, autoimmune disease, allergic disease, inflammation, ulcer, lymphoma, malignant tumor and disease related with lymphocytes infiltrate tissue. Specifically speaking, the invention relates to the method for preparing the compound in a formula (1) and its intermediate, wherein, R1 is selected from C1-4 alkyl groups, C3-6 cycloalkyl groups or C1-4 alkyl phenyl groups; R2 represents hydrogen atoms or an alkyl substituent having 1-4 carbon atoms, and also can combine with one carbon atom in a space group shown as Y to form nitrogen-containing heterocyclic radical group; and Y represents the alkyl space group having 1-4 carbon atoms. The method comprises a Heck reaction, a halogenation reaction, an alkylation reaction and an aminolysis reaction. The preparation method employs a stereospecific reaction to obtain the basically pure single (E)-formula configuration isomer intermediate, can effectively increase the purity of the intermediate, avoids the difficulty for separating the isomers, and reduces the production cost.

Discovery of S1P agonists with a dihydronaphthalene scaffold

Structure-activity relationship of sphingosine-1-phosphate receptor agonists was examined. Cinnamyl derivative 1 was modified to improve S1P 1 agonistic activity as well as selectivity over S1P3 agonistic activity. Dihydronaphthalene derivative 10d was identified as a potent S1P1 receptor agonist with high selectivity against S1P3 and enhanced efficacy in lowering peripheral lymphocyte counts in mice.